- Home
- NEGG vs ZNTL Comparison
NEGG vs ZNTL Comparison
Compare NEGG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ZNTL
- Stock Information
- Founded
- NEGG 2001
- ZNTL 2014
- Country
- NEGG United States
- ZNTL United States
- Employees
- NEGG N/A
- ZNTL N/A
- Industry
- NEGG Other Specialty Stores
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ZNTL Health Care
- Exchange
- NEGG Nasdaq
- ZNTL Nasdaq
- Market Cap
- NEGG 122.3M
- ZNTL 105.8M
- IPO Year
- NEGG 2010
- ZNTL 2020
- Fundamental
- Price
- NEGG $64.68
- ZNTL $1.36
- Analyst Decision
- NEGG
- ZNTL Buy
- Analyst Count
- NEGG 0
- ZNTL 7
- Target Price
- NEGG N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- NEGG 1.3M
- ZNTL 772.3K
- Earning Date
- NEGG 08-28-2025
- ZNTL 08-12-2025
- Dividend Yield
- NEGG N/A
- ZNTL N/A
- EPS Growth
- NEGG N/A
- ZNTL N/A
- EPS
- NEGG N/A
- ZNTL N/A
- Revenue
- NEGG $1,235,576,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- NEGG N/A
- ZNTL N/A
- Revenue Next Year
- NEGG N/A
- ZNTL N/A
- P/E Ratio
- NEGG N/A
- ZNTL N/A
- Revenue Growth
- NEGG N/A
- ZNTL N/A
- 52 Week Low
- NEGG $3.32
- ZNTL $1.01
- 52 Week High
- NEGG $69.50
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- NEGG 67.17
- ZNTL 47.40
- Support Level
- NEGG $25.49
- ZNTL $1.31
- Resistance Level
- NEGG $69.50
- ZNTL $1.48
- Average True Range (ATR)
- NEGG 9.01
- ZNTL 0.07
- MACD
- NEGG 2.65
- ZNTL -0.01
- Stochastic Oscillator
- NEGG 89.05
- ZNTL 16.67
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.